Montelukast as an Adjunct to Oral and Inhaled Steroid Therapy in Chronic Nasal Polyposis
Authors:
- 1 November 2008
- journal article
- research article
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 139 (5) , 682-687
Abstract
Objective: To examine the potential of montelukast, a leukotriene receptor antagonist, as an adjunct to oral and inhaled steroid in subjects with chronic nasal polyps.Study Design: Prospective, randomized controlled trial.Subjects and Methods: Thirty‐eight consecutive adult patients with bilateral nasal polyps were randomized into two groups. Eighteen subjects were treated with oral prednisolone for 14 days and budenoside nasal spray for 8 weeks. Twenty subjects received similar treatment with additional oral montelukast for 8 weeks. Subjects completed a modified nasal ICSD symptom score at 8 and 12 weeks after beginning treatment and the SF‐36 quality of life questionnaire at 12 weeks.Results: Symptom scores improved in both groups after treatment. Subjects treated with montelukast reported significantly less headache (P = 0.013), facial pain (P = 0.048) and sneezing (P = 0.03) than controls. Four weeks after completing treatment, no significant differences were recorded.Conclusion: Montelukast therapy may have clinical benefit as an adjunct to oral and inhaled steroid in chronic nasal polyposis, but effects are not maintained after cessation of treatment.Keywords
This publication has 19 references indexed in Scilit:
- Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fallAnnals of Allergy, Asthma & Immunology, 2002
- Leukotrienrezeptorantagonisten zur Rezidivprophylaxe bei der ASS-assoziierten Polyposis - Erste klinische Ergebnisse zur Wirkung auf entzündliche Gewebeprozesse1Laryngo-Rhino-Otologie, 2001
- Asthma and leukotrienes: antileukotrienes as novel anti‐asthmatic drugsJournal of Internal Medicine, 1999
- Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trialJournal of Allergy and Clinical Immunology, 1996
- Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD 4) receptor antagonist, in patients with chronic asthmaJournal of Allergy and Clinical Immunology, 1996
- Effect of Treatment With Zileuton, a 5-Lipoxygenase Inhibitor, in Patients With AsthmaJAMA, 1996
- Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic valueAmerican Journal of Otolaryngology, 1995
- Effects of 6 Weeks of Therapy with Oral Doses of ICI 204,219, a Leukotriene D4 Receptor Antagonist, in Subjects with Bronchial Asthma. ACCOLATE Asthma Trialists GroupAmerican Journal of Respiratory and Critical Care Medicine, 1994
- Arachidonic Acid Metabolites in Human Nasal PolypsActa Oto-Laryngologica, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992